GEN Exclusives

More »

GEN News Highlights

More »
Feb 23, 2009

Xencor Signs Antibody Optimization Deal with CSL

  • CSL inked an agreement to use Xencor’s XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies. In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.

    During the research phase of the collaboration, Xencor will provide CSL the ability to use this technology across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates that incorporate XmAb technology into development and ultimately commercialization.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?